Pancreatic cancer

Marcello Orsi; Claudio Losio; Michele Reni; Nadia Di Muzio; Francesco De Cobelli; Alessandro Del Maschio

doi:10.1007/978-88-470-2613-1_8

Pancreatic cancer

Marcello Orsi, Claudio Losio, Michele Reni, Nadia Di Muzio, Francesco De Cobelli, Alessandro Del Maschio

IRCCS Ospedale San Raffaele

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

While pancreatic cancer has an inherited or rapidly acquired chemoresistance, a meta-analysis of data from published clinical trials reported a significant improvement in overall survival (OS) among patients receiving chemotherapy [1]. Nowadays, gemcitabine is widely accepted as the standard first-line therapy and as the reference treatment arm for clinical trials in this patient population [2, 3]. However, its anti-tumoral activity is disappointing because the response rate is around 10%, median survival about 6 months, and 1-year OS around 20%.

Original language	English
Title of host publication	Imaging Tumor Response to Therapy
Publisher	Springer-Verlag Italia s.r.l.
Pages	127-140
Number of pages	14
ISBN (Print)	9788847026131, 9788847026124
DOIs	https://doi.org/10.1007/978-88-470-2613-1_8
Publication status	Published - Jan 1 2012

ASJC Scopus subject areas

Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1007/978-88-470-2613-1_8

Fingerprint Dive into the research topics of 'Pancreatic cancer'. Together they form a unique fingerprint.

Cite this

Orsi, M., Losio, C., Reni, M., Muzio, N. D., De Cobelli, F., & Maschio, A. D. (2012). Pancreatic cancer. In Imaging Tumor Response to Therapy (pp. 127-140). Springer-Verlag Italia s.r.l.. https://doi.org/10.1007/978-88-470-2613-1_8

@inbook{a3e03c70429945189fb3a45fd7715ccd,

title = "Pancreatic cancer",

abstract = "While pancreatic cancer has an inherited or rapidly acquired chemoresistance, a meta-analysis of data from published clinical trials reported a significant improvement in overall survival (OS) among patients receiving chemotherapy [1]. Nowadays, gemcitabine is widely accepted as the standard first-line therapy and as the reference treatment arm for clinical trials in this patient population [2, 3]. However, its anti-tumoral activity is disappointing because the response rate is around 10%, median survival about 6 months, and 1-year OS around 20%.",

author = "Marcello Orsi and Claudio Losio and Michele Reni and Muzio, {Nadia Di} and {De Cobelli}, Francesco and Maschio, {Alessandro Del}",

year = "2012",

month = jan,

day = "1",

doi = "10.1007/978-88-470-2613-1_8",

language = "English",

isbn = "9788847026131",

pages = "127--140",

booktitle = "Imaging Tumor Response to Therapy",

publisher = "Springer-Verlag Italia s.r.l.",

}

TY - CHAP

T1 - Pancreatic cancer

AU - Orsi, Marcello

AU - Losio, Claudio

AU - Reni, Michele

AU - Muzio, Nadia Di

AU - De Cobelli, Francesco

AU - Maschio, Alessandro Del

PY - 2012/1/1

Y1 - 2012/1/1

N2 - While pancreatic cancer has an inherited or rapidly acquired chemoresistance, a meta-analysis of data from published clinical trials reported a significant improvement in overall survival (OS) among patients receiving chemotherapy [1]. Nowadays, gemcitabine is widely accepted as the standard first-line therapy and as the reference treatment arm for clinical trials in this patient population [2, 3]. However, its anti-tumoral activity is disappointing because the response rate is around 10%, median survival about 6 months, and 1-year OS around 20%.

AB - While pancreatic cancer has an inherited or rapidly acquired chemoresistance, a meta-analysis of data from published clinical trials reported a significant improvement in overall survival (OS) among patients receiving chemotherapy [1]. Nowadays, gemcitabine is widely accepted as the standard first-line therapy and as the reference treatment arm for clinical trials in this patient population [2, 3]. However, its anti-tumoral activity is disappointing because the response rate is around 10%, median survival about 6 months, and 1-year OS around 20%.

UR - http://www.scopus.com/inward/record.url?scp=84956982194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956982194&partnerID=8YFLogxK

U2 - 10.1007/978-88-470-2613-1_8

DO - 10.1007/978-88-470-2613-1_8

M3 - Chapter

AN - SCOPUS:84956982194

SN - 9788847026131

SN - 9788847026124

SP - 127

EP - 140

BT - Imaging Tumor Response to Therapy

PB - Springer-Verlag Italia s.r.l.

ER -